Novartis to open Russian factory in mid June

1 June 2015

Swiss pharma giant Novartis (NOVN: VX) has officially confirmed that it will open its Russian manufacturing facility in St Petersburg on June 19 this year.

In contrast to other of the company’s plants, the new facility will specialize on the production of both original drugs and generics. The investment in the project is estimated at $138 million.

Details of the future range of the plant are not disclosed, but according to some sources close to the company, it will comprise of about 30 products. The drugs will be designed for the treatment of heart disease, diabetes, cancer and other diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK